Abstract
A reversible BTK inhibitor, pirtobrutinib, could be effective for patients with B-cell malignancies whose disease has worsened on other targeted therapies or who cannot tolerate the toxicity of irreversible BTK inhibitors. In a phase I/II trial, patients previously treated with other BTK inhibitors had an overall response rate of 62% to pirtobrutinib.
©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.